YUCAIPA, Calif., July 14, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading Global Medical Device manufacturer focused in the $4 Billion U.S. Respiratory Market for the growing aging and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that they have hired KGMA Business Solutions to complete the GSA filing requirements.
The Texas based KGMA was hired to complete the General Services Administration (GSA) and E-Buy filings for Ingen. KGMA maintains relationships with thousands of contracting and small business specialists within the Federal Government and Fortune 500 markets. KGMA will assist Ingen to identify, develop and deliver high-performance businesses to provide cost-effective solutions for Fortune 500 and Government agencies.
GSA serves as the acquisition and procurement arm of the federal government, offering equipment, supplies, telecommunications, and integrated information technology solutions to federal agencies so that the agencies can focus on providing products and services. As the federal government's purchasing agent, GSA connects federal purchasers with the most cost-effective and high-quality commercial products and services.
At any level of government, public purchasers search for good buys. By comparing prices, product quality, delivery terms, added services, and other determining factors, purchasers can be assured that they're spending taxpayer dollars wisely. To help state and local agencies enjoy cost savings and streamlined procedures for procuring medical technology, the U.S. Congress passed legislation to allow cooperative purchasing from federal contracts. The new Oxyview Nasal Cannula would be a very competitive product in the VA Hospitals, VA patients needing home oxygen therapy, and military medical units. The Oxyview Nasal Cannula is priced at $5.75.
"I have enjoyed working with Kenneth Kurk, the CEO of KGMA Business Solutions, and I look forward to completing the GSA filing in a swift and efficient manner. We have recently received inquiries from the United States Navy regarding the purchase of our Oxyview products," stated Scott R. Sand, Chief Executive Officer of Ingen Technologies.
Ingen submitted for GSA in 2007, and was required to meet a specific sales quota before being approved. The company has recently reached the sales quota and expects approval once KGMA has prepared and filed the revised GSA documents.
http://www.kgmasolutions.com/management.html
http://www.gsa.gov/Portal/gsa/ep/home.do?tabId=0
About Ingen Technologies/Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements:
This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.